Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Nov 8;6:36768. doi: 10.1038/srep36768

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016, The Author(s)

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

Representative images showing the immunostaining results of slow muscle-specific MHC (A–H) and dystrophin (I–P) in control and various morphant embryos, as indicated. (A,I) Regular organization of myofibers within the somite (A) and localization of dystrophin at the sarcolemma (I) in CoMO-injected embryos, with clear chevron-shape myosepta. (B–E, J–M) Individual knockdown using high amounts of MOs against lurap1 (B,J), p190RhoGEF (C,K), Golgin45 (D,L) or myo18ab (E,M) produces similar muscle lesions (B–E) and disrupts dystrophin localization (J–M) at the sarcolemma. (F–H, N–P) Simultaneous knockdown using low amounts of indicated MOs also affects myofiber integrity (F–H) and dystrophin localization (N–P), with severely disorganized myofibers and strongly disrupted myosepta in a high proportion of morphant embryos. Scale bar: 100 μm.